210 related articles for article (PubMed ID: 32850315)
1. Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1.
Castello A; Rossi S; Toschi L; Lopci E
Front Oncol; 2020; 10():1090. PubMed ID: 32850315
[No Abstract] [Full Text] [Related]
2. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT.
Kitajima K; Maruyama M; Yokoyama H; Minami T; Yokoi T; Nakamura A; Hashimoto M; Kondo N; Kuribayashi K; Kijima T; Hasegawa S; Yamakado K
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806464
[TBL] [Abstract][Full Text] [Related]
3. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
4. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
5. Comparison Between
Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
[TBL] [Abstract][Full Text] [Related]
6. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
7. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
Ayati N; Lee ST; Zakavi SR; Cheng M; Lau WFE; Parakh S; Pathmaraj K; Scott AM
J Nucl Med; 2021 Jul; 62(7):926-933. PubMed ID: 33246978
[TBL] [Abstract][Full Text] [Related]
8. Interim [
Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
[TBL] [Abstract][Full Text] [Related]
9. The role of interim
Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
[TBL] [Abstract][Full Text] [Related]
10. Predictive value and accuracy of [
Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of [
Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
[TBL] [Abstract][Full Text] [Related]
12. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
13. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
14. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
Ding Q; Cheng X; Yang L; Zhang Q; Chen J; Li T; Shi H
J Thorac Dis; 2014 Jun; 6(6):677-83. PubMed ID: 24976990
[TBL] [Abstract][Full Text] [Related]
15. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
[TBL] [Abstract][Full Text] [Related]
16. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
Park S; Lee Y; Kim TS; Kim SK; Han JY
Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
[TBL] [Abstract][Full Text] [Related]
17.
Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
Kaira K; Yamaguchi O; Naruse I; Umeda Y; Honda T; Watanabe S; Ichikawa K; Yanagisawa S; Kasahara N; Higuchi T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Iizuka K; Ishizuka T; Minato K; Suda S; Kagamu H; Mori K; Seki N; Kuji I
Cancer Imaging; 2023 Mar; 23(1):23. PubMed ID: 36859341
[TBL] [Abstract][Full Text] [Related]
19. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
[TBL] [Abstract][Full Text] [Related]
20. Tumor response assessment on imaging following immunotherapy.
Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R
Front Oncol; 2022; 12():982983. PubMed ID: 36387133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
